1,25-Dihydroxyvitamin D3 Prevents Bone Loss of the Secondary Spongiosa in Arthritic Rats by an Increase of Bone Formation and Mineralization and Inhibition of Bone Resorption

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2014 Oct 16

PMID 25315028

Citations 2

Authors

Peter Oelzner

Peter K Petrow

Gunter Wolf

Rolf Brauer

Affiliations

Soon will be listed here.

Abstract

Background: Active vitamin D metabolites have been shown to have protective effects in experimental arthritis especially when used as preventive treatment. However, because the direct effects of 1,25-dihydroxyvitamin D3 (1,25(OH) 2D3) on bone formation and resorption are very complex, the net effect of 1,25(OH)2D3 on histomorphometric parameters of bone turnover and mineralisation should be investigated. Therefore, we examined the influence of 1,25(OH)2D3 therapy on arthritis-induced alterations of periarticular and axial bone as well as disease activity, inflammation and joint destruction in antigen-induced arthritis (AIA) of the rat.

Methods: AIA was induced in 20 eight-week-old female Wistar rats. 10 rats without arthritis were used as healthy controls. AIA rats received 1,25(OH)2D3 (0.2 μg/kg/day, i.p., n = 10) or vehicle (n = 10) at regular intervals for 28 consecutive days beginning 3 days before arthritis induction. Bone structure of the secondary spongiosa of the periarticular and axial bone was analyzed using histomorphometry. Parameters of mineralization were investigated using tetracycline labelling. Clinical disease activity, inflammation and joint destruction were measured by joint swelling and histological investigation, respectively.

Results: AIA led to significant periarticular bone loss. 1,25(OH)2D3 treatment resulted in a highly significant increase in trabecular bone volume and bone formation rate in comparison to both vehicle-treated AIA and healthy controls at periarticular (p < 0.01 and p < 0.001, respectively) and axial bone (p < 0.001 and p < 0.001, respectively). In addition, bone resorption was reduced by 1,25(OH)2D3 at the axial bone (p < 0.05 vs. vehicle-treated AIA). Joint swelling as well as histological signs of inflammation and joint destruction were not influenced by 1,25(OH)2D3.

Conclusions: The results of the study indicate a marked osteoanabolic effect of 1,25(OH)2D3 presumably due to a substantial increase in mineralization. Thus, 1,25(OH)2D3 may be an effective osteoanabolic treatment principle to antagonize the inflammation-associated suppression of bone formation in rheumatoid arthritis.

Citing Articles

Endocrine Disruptor-Induced Bone Damage Due to Hormone Dysregulation: A Review.

Iwobi N, Sparks N Int J Mol Sci. 2023; 24(9).

PMID: 37175969 PMC: 10179611. DOI: 10.3390/ijms24098263.

A single intra-articular dose of vitamin D analog calcipotriol alleviates synovitis without adverse effects in rats.

Huhtakangas J, Huovinen J, Laaksonen S, Voipio H, Vuolteenaho O, Finnila M PLoS One. 2021; 16(4):e0250352.

PMID: 33878143 PMC: 8057567. DOI: 10.1371/journal.pone.0250352.

References

Rauner M, Sipos W, Pietschmann P . Osteoimmunology. Int Arch Allergy Immunol. 2006; 143(1):31-48. DOI: 10.1159/000098223. View

Neumann T, Oelzner P, Petrow P, Thoss K, Hein G, Stein G . Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. Inflamm Res. 2006; 55(1):32-9. DOI: 10.1007/s00011-005-0005-5. View

Oelzner P, Schwabe A, Lehmann G, Eidner T, Franke S, Wolf G . Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int. 2008; 28(11):1143-50. DOI: 10.1007/s00296-008-0576-x. View

Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H . Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000; 275(3):768-75. DOI: 10.1006/bbrc.2000.3379. View

Hewison M . Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010; 39(2):365-79, table of contents. PMC: 2879394. DOI: 10.1016/j.ecl.2010.02.010. View

Tsuji M, Fujii K, Nakano T, Nishii Y . 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett. 1994; 337(3):248-50. DOI: 10.1016/0014-5793(94)80201-7. View

Giner M, Montoya M, Vazquez M, Rios M, Moruno R, Miranda M . Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts. Horm Metab Res. 2008; 40(12):869-74. DOI: 10.1055/s-0028-1082083. View

Cutolo M, Straub R . Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther. 2009; 11(2):218. PMC: 2688171. DOI: 10.1186/ar2630. View

Takasu H . Anti-osteoclastogenic action of active vitamin D. Nutr Rev. 2008; 66(10 Suppl 2):S113-5. DOI: 10.1111/j.1753-4887.2008.00098.x. View

10.

Adams J, Hewison M . Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4(2):80-90. PMC: 2678245. DOI: 10.1038/ncpendmet0716. View

11.

Murakami H, Nakamura T, Tsurukami H, Abe M, Barbier A, Suzuki K . Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. J Bone Miner Res. 1994; 9(9):1355-64. DOI: 10.1002/jbmr.5650090906. View

12.

Boissier M, Chiocchia G, Fournier C . Combination of cyclosporine A and calcitriol in the treatment of adjuvant arthritis. J Rheumatol. 1992; 19(5):754-7. View

13.

Binderup L . Bone changes in rats with adjuvant arthritis: treatment with 1 alpha-hydroxycholecalciferol. Acta Pharmacol Toxicol (Copenh). 1986; 59(3):228-35. DOI: 10.1111/j.1600-0773.1986.tb00159.x. View

14.

Rauner M, Sipos W, Goettsch C, Wutzl A, Foisner R, Pietschmann P . Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res. 2008; 24(1):78-86. DOI: 10.1359/jbmr.080902. View

15.

Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D . Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007; 56(7):2143-9. DOI: 10.1002/art.22722. View

16.

Zhang Y, Leung D, Richers B, Liu Y, Remigio L, Riches D . Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012; 188(5):2127-35. PMC: 3368346. DOI: 10.4049/jimmunol.1102412. View

17.

Wruck C, Fragoulis A, Gurzynski A, Brandenburg L, Kan Y, Chan K . Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis. 2010; 70(5):844-50. DOI: 10.1136/ard.2010.132720. View

18.

van Hamburg J, Asmawidjaja P, Davelaar N, Mus A, Cornelissen F, van Leeuwen J . TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis. 2012; 71(4):606-12. DOI: 10.1136/annrheumdis-2011-200424. View

19.

Lempert U, Minne H, Albrecht B, Scharla S, Matthes F, Ziegler R . 1,25-Dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner. 1989; 7(2):149-58. DOI: 10.1016/0169-6009(89)90072-x. View

20.

Erben R, Scutt A, Miao D, Kollenkirchen U, Haberey M . Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology. 1997; 138(11):4629-35. DOI: 10.1210/endo.138.11.5511. View